The 340B drug discount program is causing a rise in the costs of treating cancer patients, according to a new report.
Federal prosecutors earlier this week filed a complaint against the Memphis Methodist health system, taking over a qui tam action initially filed by private whistleblowers, who alleged that Methodist’s six-year arrangement with West Clinic, an oncology private practice, violated the Anti-Kickback Statute and the False Claims Act.
